WRBC
BBOT

W.R. Berkley Corp’s BridgeBio Oncology BBOT Stock Holding History

W.R. Berkley Corp’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-445,195
Closed -$4.73M – 271
2025
Q2 		$4.73M Buy
+445,195
New +$4.81M 0.25% 78

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

W.R. Berkley Corp's BBOT Position: Q3 2025 in Review

W.R. Berkley Corp sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 445,195 shares — an estimated $4.73M sold.

W.R. Berkley Corp first reported a position in BBOT in Q2 2025 and held it in 1 quarter. The position peaked at $4.73M in Q2 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • W.R. Berkley Corp reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • W.R. Berkley Corp sold 445,195 BridgeBio Oncology shares in Q3 2025, an estimated $4.73M.
  • W.R. Berkley Corp first reported a position in BridgeBio Oncology in Q2 2025 and held it in 1 quarter.
  • W.R. Berkley Corp's BridgeBio Oncology position peaked at $4.73M in Q2 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on W.R. Berkley Corp's 13F filing for Q3 2025, filed 14 Nov 2025.